We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks.com featured highlights Catalyst Pharmaceuticals, SunOpta, Gambling.com and Orion Group
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 24, 2025 – The stocks in this week’s article are Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) , SunOpta Inc. (STKL - Free Report) , Gambling.com Group Ltd. (GAMB - Free Report) and Orion Group Holdings, Inc. (ORN - Free Report) .
Rising Cash Flows Make These 4 Stocks Worth Choosing Now
We are already into the second-quarter reporting cycle, and stocks with top-line growth and increasing profit numbers might be popular choices. Moreover, choosing stocks based on a company’s efficiency in generating cash flows can be far more rewarding.
In this regard, stocks such as Catalyst Pharmaceuticals, Inc., SunOpta Inc., Gambling.com Group Ltd. and Orion Group Holdings, Inc. are worth buying.
This is because even a profit-making company can have a dearth of cash flow and become bankrupt while meeting its obligations if its profits are not channeled in the right direction. However, a company can effectively weather any market mayhem if it has a solid cash position, as that lends a company the flexibility to make decisions, the means to invest and the fuel to run its growth engine. It is indeed the key to a company’s existence, development and success and reveals its true financial health.
Furthermore, with uncertainties in the global economy, market disruptions and dislocations, as well as liquidity concerns, analyzing a company’s cash-generating efficiency holds more relevance.
To figure out this efficiency, one needs to consider a company’s net cash flow. While in any business, cash moves in and out, it is net cash flow that explains how much money a company is actually generating.
If a company is experiencing a positive cash flow, it denotes an increase in its liquid assets, which gives it the means to meet debt obligations, shell out for expenses, reinvest in the business, endure downturns and finally return wealth to shareholders. On the other hand, a negative cash flow indicates a decline in the company’s liquidity, which in turn lowers its flexibility to support these moves.
However, having a positive cash flow merely does not secure a company’s future growth. To ride on the growth curve, a company must have its cash flow increasing because that indicates management’s efficiency in regulating its cash movements and less dependency on outside financing for running its business.
Therefore, keep yourself abreast with the following screen to bet on stocks with rising cash flows.
Here are four out of the six stocks that qualified for the screening:
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare and difficult-to-treat diseases.
The Zacks Consensus Estimate for Catalyst Pharmaceuticals’ 2025 earnings has been revised upward by 2 cents to $2.25 per share in the past 60 days. CPRX has a VGM Score of A.
SunOpta provides tailored supply-chain innovations and solutions to leading brands, retailers and foodservice companies, spanning a wide range of beverages, broths and nutritious snack offerings.
The Zacks Consensus Estimate for SunOpta’s 2025 EPS is pegged at 18 cents, suggesting a surge of 63.6% from the year-ago reported figure. STKL has a VGM Score of B.
Gambling.com offers marketing and sports data services to the global online gambling industry. It supports iGaming and sports betting operators in acquiring customers across 19 national markets and more than ten languages through a portfolio of leading branded websites like Gambling.com, Bookies.com and Casinos.com.
The Zacks Consensus Estimate for Gambling.com’s 2025 earnings has been revised upward by a cent to $1.07 per share in the past 30 days. GAMB has a VGM Score of A.
Orion Group is a construction company that provides services on and off the water primarily in the continental United States, Alaska, Canada and the Caribbean Basin. The company's operating segment consists of the heavy civil marine construction segment and the commercial concrete segment.
The Zacks Consensus Estimate for Orion Group’s 2025 earnings has been revised upward by a cent to 17 cents per share over the past seven days. ORN has a VGM Score of A.
Get the rest of the stocks on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and back-testing software.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks.com featured highlights Catalyst Pharmaceuticals, SunOpta, Gambling.com and Orion Group
For Immediate Release
Chicago, IL – July 24, 2025 – The stocks in this week’s article are Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) , SunOpta Inc. (STKL - Free Report) , Gambling.com Group Ltd. (GAMB - Free Report) and Orion Group Holdings, Inc. (ORN - Free Report) .
Rising Cash Flows Make These 4 Stocks Worth Choosing Now
We are already into the second-quarter reporting cycle, and stocks with top-line growth and increasing profit numbers might be popular choices. Moreover, choosing stocks based on a company’s efficiency in generating cash flows can be far more rewarding.
In this regard, stocks such as Catalyst Pharmaceuticals, Inc., SunOpta Inc., Gambling.com Group Ltd. and Orion Group Holdings, Inc. are worth buying.
This is because even a profit-making company can have a dearth of cash flow and become bankrupt while meeting its obligations if its profits are not channeled in the right direction. However, a company can effectively weather any market mayhem if it has a solid cash position, as that lends a company the flexibility to make decisions, the means to invest and the fuel to run its growth engine. It is indeed the key to a company’s existence, development and success and reveals its true financial health.
Furthermore, with uncertainties in the global economy, market disruptions and dislocations, as well as liquidity concerns, analyzing a company’s cash-generating efficiency holds more relevance.
To figure out this efficiency, one needs to consider a company’s net cash flow. While in any business, cash moves in and out, it is net cash flow that explains how much money a company is actually generating.
If a company is experiencing a positive cash flow, it denotes an increase in its liquid assets, which gives it the means to meet debt obligations, shell out for expenses, reinvest in the business, endure downturns and finally return wealth to shareholders. On the other hand, a negative cash flow indicates a decline in the company’s liquidity, which in turn lowers its flexibility to support these moves.
However, having a positive cash flow merely does not secure a company’s future growth. To ride on the growth curve, a company must have its cash flow increasing because that indicates management’s efficiency in regulating its cash movements and less dependency on outside financing for running its business.
Therefore, keep yourself abreast with the following screen to bet on stocks with rising cash flows.
Here are four out of the six stocks that qualified for the screening:
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare and difficult-to-treat diseases.
The Zacks Consensus Estimate for Catalyst Pharmaceuticals’ 2025 earnings has been revised upward by 2 cents to $2.25 per share in the past 60 days. CPRX has a VGM Score of A.
SunOpta provides tailored supply-chain innovations and solutions to leading brands, retailers and foodservice companies, spanning a wide range of beverages, broths and nutritious snack offerings.
The Zacks Consensus Estimate for SunOpta’s 2025 EPS is pegged at 18 cents, suggesting a surge of 63.6% from the year-ago reported figure. STKL has a VGM Score of B.
Gambling.com offers marketing and sports data services to the global online gambling industry. It supports iGaming and sports betting operators in acquiring customers across 19 national markets and more than ten languages through a portfolio of leading branded websites like Gambling.com, Bookies.com and Casinos.com.
The Zacks Consensus Estimate for Gambling.com’s 2025 earnings has been revised upward by a cent to $1.07 per share in the past 30 days. GAMB has a VGM Score of A.
Orion Group is a construction company that provides services on and off the water primarily in the continental United States, Alaska, Canada and the Caribbean Basin. The company's operating segment consists of the heavy civil marine construction segment and the commercial concrete segment.
The Zacks Consensus Estimate for Orion Group’s 2025 earnings has been revised upward by a cent to 17 cents per share over the past seven days. ORN has a VGM Score of A.
Get the rest of the stocks on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and back-testing software.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2608110/rising-cash-flows-make-these-4-stocks-worth-choosing-now
Follow us on Twitter: https://www.twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.